KERSEY FADDUOL: Open Payments
NPI 1730838400 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,008 in 47 payments from 9 companies in 2025. Trend: 2023 $21 · 2024 $695 · 2025 $1,008
Food & beverage: $1,008
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 15 | $266 |
| Novo Nordisk Inc | 10 | $229 |
| Lilly USA, LLC | 6 | $142 |
| Exeltis, USA Inc. | 5 | $110 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $72 |
| Amgen Inc. | 3 | $71 |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $60 |
| MILLICENT US INC | 2 | $36 |
| Cepheid | 1 | $23 |
Products named: MYFEMBREE, MOUNJARO, Wegovy, SLYND, XIFAXAN, EVENITY, Ozempic, Saxenda.
Industry payments across CA — which companies pay providers there.
